Form 4: Vera Therapeutics Director Beth C. Seidenberg Acquires 14,000 Stock Options

Director Beth C. Seidenberg acquired 14,000 stock options in Vera Therapeutics, Inc. on May 14, 2025.

Summary

• On May 14, 2025, Beth C. Seidenberg, a director of Vera Therapeutics, Inc., acquired 14,000 stock options.
• The exercise price of these options is $21.19.
• The options vest fully on the earlier of the first anniversary of the grant date or the date of the Company's 2026 annual stockholder meeting, contingent upon continuous service.
• The options also vest fully upon a change in control, subject to continuous service through that date.
• The expiration date for these options is May 13, 2035.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The vesting schedule of the options is tied to the director's continuous service and a potential change in control, suggesting a focus on long-term commitment and alignment with shareholder interests.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management and shareholders by incentivizing long-term value creation.

Stakeholder Impact

• The acquisition of stock options by a director can positively influence shareholder confidence.

Key Dates

Keywords

stock options, director, Vera Therapeutics, beneficial ownership, Form 4, Seidenberg, VERA